Related Experiment Video

Updated: May 21, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K

Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)

Omali Pitiyarachchi1, Aaron C Tan2,3

  • 1School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.

Translational Lung Cancer Research
|March 21, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
HER2 overexpressionantibody drug conjugate (ADC)non-small cell lung cancer (NSCLC)

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

1.9K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K